Femasys (FEMY) announced the appointment of Kenneth D. Eichenbaum, to its Board of Directors. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fellowship at Stanford University Medical Center and earned his M.D. from the Icahn School of Medicine at Mount Sinai, with additional degrees in engineering from the University of Pennsylvania and in finance from The Wharton School. The Company also expresses its appreciation to Joshua Silverman for his service on the Board of Directors. His capital markets perspective and strategic counsel supported Femasys during a period of important growth and development.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FEMY:
- Femasys advances FemBloc to U.S. approval with initiation of trial enrollment
- Femasys initiated with a Buy at Lake Street
- Femasys’s FemBloc Pivotal Trial Update: What Investors Should Watch in Women’s Health
- Femasys FemBloc achieved certification under MDSAP
- Femasys receives AMA CPT Editorial Panel approval for new CPT code
